CV Therapeutics Inc - Current report filing (8-K)
May 30 2008 - 2:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 05/27/2008
CV THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-21643
Delaware
|
|
43-1570294
|
(State or other jurisdiction of
|
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
3172 Porter Drive, Palo Alto, CA 94304
(Address of principal executive offices, including zip code)
650-384-8500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On May 27, 2008, we publicly disseminated a press release announcing that two clinical abstracts have been accepted for presentation at the American Diabetes Association (ADA) 68th Scientific Sessions, which will be held in San Francisco, CA on June 6 - 10, 2008.
The foregoing description is qualified in its entirety by reference to our press release dated May 27, 2008, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
* * * * *
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release dated May 27, 2008.
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
CV THERAPEUTICS, INC.
|
|
|
Date: May 30, 2008
|
|
|
|
By:
|
|
/s/ DANIEL K. SPIEGELMAN
|
|
|
|
|
|
|
|
|
DANIEL K. SPIEGELMAN
|
|
|
|
|
|
|
|
|
Senior Vice President and Chief Financial Officer
|
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
EX-99.1
|
|
Press Release dated May 27, 2008.
|
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024
See More Message Board Posts